Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously ...

NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses ...

Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program will consist of a series of studies designed to support ...

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...

Vivani Medical began the LIBERATE-1 trial, testing a six-month exenatide implant for chronic weight management in Australia. The study uses NanoPortal technology, with results expected in mid-2025 and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Previous studies suggest GLP-1 receptor agonists may ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. A large-scale clinical trial found ...